Teva Global Economic Impact Report · Teva Economic Impact Report 5 In 2018, Teva’s economic...

TevaGlobal Economic Impact Report

January 2020

Teva Economic Impact Report 2

Table of Contents3 About This Report

4 Global Impact

Teva North America

8 United States

13 Canada

Teva Europe

16 Bulgaria

18 Croatia

20 Czech Republic

22 France

24 Germany

26 Hungary

28 Ireland

30 Italy

32 Netherlands

34 Poland

36 Spain

38 United Kingdom

Teva International Markets

40 Chile

42 Israel

44 Japan

46 Russia

48 Ukraine

3 Teva Economic Impact Report

Teva Pharmaceutical Industries Ltd. develops, manufactures and delivers innovative specialty medicines and quality, affordable generics for millions of people across the globe, saving patients and healthcare systems billions of dollars every year. The company’s operations, including research and development and manufacturing, result in high-quality jobs, tax revenues and growing economic outputs for communities around the world.

Based on independent analyses conducted by Matrix Global Advisors (MGA), this report highlights Teva’s wide-ranging economic benefits and quantifies Teva’s direct and indirect economic impact in terms of jobs, labor income, gross domestic product (GDP) and generic drug savings. MGA uses IMPLAN models of specific countries to show how Teva’s and Teva employees’ expenditures ripple through economies around the world. Nineteen key countries are examined in this report. Rotem Strategy provided analytics for one country, Israel.

This report was funded by Teva and conducted based on Teva and industry data. Teva had no role in the design, methodology, determination or interpretation of the results.

About Matrix Global Advisors (MGA)MGA is an economic policy consulting firm in Washington, DC, specializing in fiscal, healthcare and tax policy matters. MGA helps Fortune 500 companies, trade associations, healthcare providers, investment banks and others understand and convey the economics of policy issues.

About the IMPLAN Model

IMPLAN’s regional input-output models are widely used across government, academia, non-profit and corporate settings. Drawing on publicly available historical economic data, the models project economic indicators (e.g., production and employment levels) by industry. Teva’s actual payroll and operating expenses data serve as inputs to the IMPLAN model, allowing MGA to capture Teva’s positive economic impact.

About TevaTeva Pharmaceutical Industries Ltd. is the world’s leading provider of generic medicines, offering quality medicines and treatments to patients. Teva also has a growing portfolio of innovative specialty, or branded, medicines and biopharmaceutical products, with a promising pipeline focused on medicines for central nervous system disorders, oncology and respiratory diseases. Teva’s mission is to be a global leader in generics and biopharmaceuticals, improving the lives of patients. The company has 3,500 products in its portfolio and serves around 200 million people each day.

http://www.getmga.com/


Teva’s Global ImpactTeva is the world’s leading provider of generic medicines, with an innovative biopharmaceutical portfolio, including specialty medicines, over-the-counter products and active pharmaceutical ingredients (APIs). In 2018, the company produced 80 billion tablets and capsules and 650 million sterile units.

In 2018, Teva’s workforce consisted of 42,535 employees* across 60 countries (Figure 1). Of these, 12 countries had more than 1,000 employees each and more than 30 countries had more than 200 employees each.

Manufacturing sites in Bulgaria, Croatia, the Czech Republic, Germany, Hungary, India, Israel, Spain and Poland make up the majority of Teva’s production capacity. Teva’s API facilities include two large development centers in India and Croatia focused on synthetic products, a center in Hungary specializing in fermentation and semi-synthetic products, a center in Israel for oligonucleotides and a center in the Czech Republic for high-potency APIs.

Teva’s research and development (R&D) activities span the breadth of its business, including generic medicines (e.g., finished goods and APIs), specialty pharmaceuticals, biopharmaceuticals and over-the-counter medicines. In 2018, Teva spent more than $1.2 billion on R&D activities and had more than 1,550 generic products in its pipeline.

Figure 1. Teva’s Workforce in 2018

Total 42,535

19,236

11,351

7,0564,893

In 2018, Teva:

Employed 42,535 people across 60 countries

Produced 80 billion tablets and capsules and 650 million sterile units

Spent more than $1.2B on R&D activities

and had more than 1,550 generic products

in its pipeline

Region

United States

Israel Rest of World

Europe

Note: Total may differ from sum of numbers due to rounding.

*Refers to full-time equivalent employees.


In 2018, Teva’s economic activity supported nearly

230,000 jobs and contributed

$50.7B to GDP across 19 countries

Positively Impacting Economies Around the WorldAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional gross domestic product (GDP).

This report, from Matrix Global Advisors (MGA), highlights Teva’s global impact on economies, with a focus on 19 of the 60 countries in which Teva operates. Based on a detailed impact analysis, Teva’s local purchases and payroll support nearly 230,000 jobs across these 19 countries and contribute $50.7 billion to GDP. Figure 2 highlights the number of Teva employees in these 19 countries, and Figure 3 summarizes Teva’s contribution to employment, GDP and labor income.

Employees in these 19 countries represent 77% of Teva’s workforce and 85% of Teva’s direct economic activity. The remainder of Teva’s employees are spread out across 41 other countries, with a large industrial presence in India and Mexico.

An approximate analysis of Teva’s activities in these 41 countries indicates Teva’s employment and spending support an additional $10 billion in economic activity. In total, Teva’s economic activity contributed an estimated $60.7 billion to GDP in 2018.

Canada: 962

Ireland: 707

France: 326

Spain: 817

Italy: 1,305

Ukraine: 331

Israel: 4,812

Bulgaria: 1,698

Hungary: 2,119

Croatia: 2,265

Japan: 1,602

US: 6,794

Chile: 811

Russia: 933Poland: 1,124

Czech Republic: 1,598

Germany: 2,553

Netherlands: 833

UK: 1,289

Figure 2. Teva Employees in Select Countries in 2018


Figure 3. Teva’s Macroeconomic Impact in Select Countries in 2018 (Labor Income and GDP in $)

BulgariaJobs: 5,708

Labor Income:64,434,000

GDP:370,336,000

CanadaJobs: 6,081


GDP:1,034,937,000

CroatiaJobs: 6,624


GDP:676,307,000

ChileJobs: 4,534


GDP:415,996,000

Czech RepublicJobs: 8,491


GDP:1,449,532,000

FranceJobs: 6,352


GDP:1,959,130,000

GermanyJobs: 15,990


GDP:5,446,211,000

IrelandJobs: 1,238


GDP:425,152,000

IsraelJobs: 19,079

Labor Income:Not calculated

GDP:2,964,000,000

HungaryJobs: 8,350


GDP:734,349,000

NetherlandsJobs: 3,235


GDP:1,700,280,000

United StatesJobs: 57,333

Labor Income:4,767,648,000

GDP:15,016,004,000

United KingdomJobs: 30,461

Labor Income:1,278,470,000

GDP:8,241,717,000

Total Jobs: 229,936 Total Labor Income:

9,960,795,000 Total GDP:

50,675,546,000

UkraineJobs: 2,089


GDP:449,753,000

ItalyJobs: 7,877


GDP:2,101,635,000

PolandJobs: 11,875


GDP:1,714,785,000

SpainJobs: 6,428


GDP:1,254,454,000

JapanJobs: 9,446


GDP:2,761,060,000

RussiaJobs: 18,746


GDP:1,959,909,000

Note: Macroeconomic results reflect the impact of Teva employment and spending in each country in 2018. Total labor income does not include Israel. Total may differ from sum of numbers due to rounding.


Driving Savings and Access with Generic MedicinesAs a leading provider of generic medicines globally, the leading provider in the US and a top three provider in more than 30 countries, Teva provides savings to healthcare systems around the world through its generic medicines. According to an analysis by MGA, Teva’s generic savings in select countries totaled $54.6 billion in 2018 (Table 1).

Country Teva Generic Savings ($ Millions)

Bulgaria 21

Canada 3,000

Chile 132

Czech Republic 37

France 238

Germany 2,100

Hungary 26

Ireland 86

Israel 400

Italy 940

Japan 355

Netherlands 856

Poland 88

Russia 173

Spain 104

Ukraine 18

United Kingdom 4,100

United States 41,900

Table 1. Teva’s Generic Drug Savings in Select Countries in 2018

In 2018, Teva:

Received the EcoVadis Silver Medal (top 16% of pharmaceutical companies) for responsible conduct in environment, labor and human rights practices, ethics and sustainable procurement

Donated $380M worth of medicines to patients around the world

Received more than 900 generic medicine approvals

Provided $43M worth of medicines to patient assistance organizations

Making a Positive Social ImpactIn addition to making an economic impact, Teva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities, patients and caregivers around the world through monetary and product donations, employee volunteering, programs and partnerships.


Teva in the United StatesWith nearly 6,800 employees in the United States (US), Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in the US, manufacturing more than 500 generic prescription and over-the-counter products in more than 2,000 dosage strengths and package sizes, including oral solid dosage forms, injectable products, inhaled products, liquids, ointments and creams. Approximately one of every seven generic prescriptions in the US is filled with a Teva product.1

1. MGA estimate based on IQVIA, 2018; MAT 2018.

Teva’s economic activity:

$41.9B in generic savings

attributable to Teva

1 of 7 generic prescriptions

filled with a Teva product

supported

57,300+jobs

generated

$4.8Bin labor income

contributed

$15.0Bto gross domestic

product (GDP)


Positively Impacting the US EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 57,300 full-time jobs, contributing $15.0 billion to GDP and generating $4.8 billion in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Table 1. Teva’s Macroeconomic Impact in the US in 2018


Jobs

Labor Income ($ Millions)

GDP ($ Millions)

Teva’s Direct Economic Activity 6,794 1,020.5 5,692.3

Economic Activity Supported by Teva 50,539 3747.1 9,323.6

Total 57,333 4767.6 15,016.0

Driving Savings and Access With Generic MedicinesHealthcare system savings

In 2018, generic drugs saved the US healthcare system an estimated $292.6 billion.2 As the largest generic medicines manufacturer in the US, Teva is responsible for $41.9 billion of these savings.3 See Figure 1 for savings attributable to Teva by payor. See Figure 2 and Tables 2 and 3 for savings attributable to Teva by state and category.

Patient savings and access

Teva’s generic medicines provide significant out-of-pocket savings to patients. In the US, the average copay for a generic medicine ($5.63) is roughly one-seventh of the average copay for a branded medicine ($40.65), and more than 95% of generic medicine prescriptions cost patients $20 or less.2

2. Association for Accessible Medicines (AAM), 2019. Generic Drug and Biosimilars Access and Savings in the U.S. Available: https://accessiblemeds.org/resources/blog/2019-generic-drug-and-biosimilars-access-savings-us-report

3. MGA estimate based on Teva’s generic market share in the US in 2018 and National Health Expenditure Accounts, CY 2018, Table 19. 4. Express Scripts, 2015. The Costs of Nonadherence.

Figure 1. Teva’s $41.9 Billion in US Generic Savings by Payor ($ Billions)

Out of Pocket

Private Insurance

Government

$19.2

$5.9

$16.8

Affordable generic medicines also improve patient access and medication adherence. Medication non-adherence occurs when patients do not take prescription medicines as directed, and this can lead to additional costs. Prescription cost is one contributing factor to patients not taking medicines as prescribed. As a result, generic drugs play an important role in addressing non-adherence.4

Teva saved the US healthcare system

$41.9B in 2018, including

$5.9B in savings to patients


Figure 2. Teva’s Generic Savings by State in 2018

Table 2. Teva’s Generic Savings by State in 2018 ($ Millions)

0-250250-750750-12501250-17501750-22502250+

<$250

$251-750

$751-1,250

$1,251-1,750

$1,751-2,250

$2,251+

Savings ($ Millions)

State Total

Alabama $847

Alaska $53

Arizona $781

Arkansas $525

California $3,693

Colorado $470

Connecticut $482

Delaware $131

District of Columbia

$72

Florida $2,724

Georgia $1,398

Hawaii $139

Idaho $191

Illinois $1,556

Indiana $936

Iowa $453

Kansas $386

State Total

Kentucky $908

Louisiana $844

Maine $168

Maryland $700

Massachusetts $949

Michigan $1,388

Minnesota $606

Mississippi $528

Missouri $856

Montana $120

Nebraska $268

Nevada $340

New Hampshire

$177

New Jersey $1,145

New Mexico $227

New York $3,023

North Carolina $1,423

State Total

North Dakota $89

Ohio $1,760

Oklahoma $497

Oregon $443

Pennsylvania $1,906

Rhode Island $181

South Carolina

$770

South Dakota $100

Tennessee $1,084

Texas $3,283

Utah $326

Vermont $76

Virginia $1,032

Washington $762

West Virginia $361

Wisconsin $665

Wyoming $60

United States $41,901Note: Total may differ from sum of numbers due to rounding.


Note: These calculations are based on a national estimate of Teva’s generic savings in the US and a distribution of pharmacy prescriptions by state and category from Kaiser Family Foundation. “Cash” refers to patients who pay cash for their prescriptions and does not include copays or coinsurance payments. Total may differ from sum of numbers due to rounding.

Table 3. Teva’s Generic Savings by State and Category in 2018 ($ Millions)

State Commercial Medicare Medicaid Cash TotalAlabama $451 $257 $70 $69 $847Alaska $33 $8 $9 $3 $53Arizona $392 $213 $142 $34 $781Arkansas $276 $155 $51 $42 $525California $1,689 $1,032 $811 $162 $3,693Colorado $260 $111 $75 $23 $470Connecticut $242 $128 $95 $16 $482Delaware $62 $37 $27 $5 $131District of Columbia $37 $13 $20 $3 $72Florida $1,372 $897 $272 $183 $2,724Georgia $749 $388 $161 $100 $1,398Hawaii $64 $36 $33 $6 $139Idaho $108 $50 $20 $13 $191Illinois $809 $426 $250 $72 $1,556Indiana $488 $255 $147 $46 $936Iowa $224 $136 $74 $20 $453Kansas $229 $105 $30 $22 $386Kentucky $358 $254 $244 $52 $908Louisiana $387 $222 $191 $44 $844Maine $83 $60 $20 $6 $168Maryland $388 $146 $138 $27 $700Massachusetts $464 $274 $184 $26 $949Michigan $641 $390 $292 $65 $1,388Minnesota $305 $165 $104 $32 $606Mississippi $282 $169 $23 $55 $528Missouri $442 $270 $95 $49 $856Montana $55 $34 $23 $8 $120Nebraska $148 $76 $27 $17 $268Nevada $178 $83 $63 $16 $340New Hampshire $106 $48 $17 $6 $177New Jersey $615 $274 $203 $53 $1,145New Mexico $126 $57 $33 $12 $227New York $1,312 $827 $782 $102 $3,023North Carolina $750 $441 $150 $82 $1,423North Dakota $49 $24 $7 $8 $89Ohio $819 $462 $414 $64 $1,760Oklahoma $281 $136 $49 $31 $497Oregon $211 $132 $79 $21 $443Pennsylvania $920 $582 $337 $67 $1,906Rhode Island $83 $50 $43 $5 $181South Carolina $403 $237 $84 $46 $770South Dakota $55 $31 $8 $7 $100Tennessee $562 $327 $126 $69 $1,084Texas $1,922 $820 $333 $208 $3,283Utah $221 $61 $21 $22 $326Vermont $34 $25 $16 $2 $76Virginia $642 $248 $91 $51 $1,032Washington $419 $172 $140 $31 $762West Virginia $146 $109 $91 $15 $361Wisconsin $337 $194 $105 $29 $665Wyoming $37 $14 $4 $4 $60United States $21,267 $11,658 $6,826 $2,151 $41,901


Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in the US and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva’s 2018 Social Impact highlights in the US:

• Contributed $23.4 million worth of medications to patients who struggle to afford medicines through Teva Cares Foundation Patient Assistance Programs

• Provided $20 million worth of medicines through the AssistRX-run HUB service

• Worked with Volunteers in Medicine to provide healthcare services to those without access

• Provided funding for Enhancing Access2Care, which helps patients with multiple chronic conditions receive access to primary and preventive healthcare

• Sponsored Miles for Migraine, which hosts walk/run events and Patient Education Days

• Funded a STEM program for high school students with The College of Physicians of Philadelphia

Teva’s US Supplier Diversity in 2018

330 small businesses

50 women-owned small businesses

5 small, disadvantaged businesses

13


Teva Economic Impact Report

Teva in Canada With nearly 1,000 employees in Canada, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is a leading generic drug company in Canada, manufacturing more than 350 generic prescription and over-the-counter products. Approximately one of every six generic prescriptions in Canada is filled with a Teva product.1


C$3.8B (US$3.0B) in generic savings attributable

to Teva



supported nearly

6,100 jobs

generated

C$325M (US$254M) in labor income

contributed

C$1.3B(US$1.0B) to gross

domestic product (GDP)


Positively Impacting Canada’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 6,100 full-time jobs, contributing C$1.3 billion (US$1.0 billion) to GDP and generating C$325 million (US$254 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines

Teva saved Canada’s healthcare systemC$3.8B (US$3.0Bin 2018

Table 1. Teva’s Macroeconomic Impact in Canada in 2018


Jobs Labor Income (Millions)

GDP (Millions)

C$ US$ C$ US$

Teva’s Direct Economic Activity 962 84.3 66.0 417.2 326.5

Economic Activity Supported by Teva 5,119 240.2 188.0 905.2 708.5

Total 6,081 324.6 254.0 1,322.4 1,034.9

In 2018, generic drugs saved Canada’s healthcare system an estimated C$24.4 billion (US$19.1 billion), representing approximately 72% of prescriptions but comprising only 20% of prescription drug spending.2 As the leading generic drug manufacturer in Canada, Teva is responsible for C$3.8 billion (US$3.0 billion) of these savings.3

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Canada and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva’s 2018 Social Impact highlights in Canada:

• Donated C$105 million (US$79 million) worth of medicines to Health Partners International Canada since 1985

• Donated C$1.8 million (US$1.4 million) since 2008 to Childhood Cancer Canada for childhood cancer programs and services, including more than 1,000 Survivor Scholarships, which support post-secondary academic aspirations of adult cancer survivors

2. Canadian Generic Pharmaceutical Association.

3. MGA estimate based on Teva’s generic market share in Canada in 2018.

15

Czech Republic8,491


Teva’s Impact in EuropeTeva is the leading generic drug company in Europe, with a specialty portfolio focused on central nervous system disorders, respiratory diseases and oncology.

In 2018, Teva employed 19,236 people in Europe. Teva has

manufacturing sites in Bulgaria, Croatia, the Czech Republic, Germany, Hungary, Poland and Spain. In total, Teva operated 31 manufacturing and research and development facilities across Europe in 2018.

Teva’s economic activity generated

$3.9B in labor income and contributed

$26.1B to GDP across 12 European countries in 2018

Teva saved healthcare systems in Europe more than $8.6B in 2018

Positively Impacting Europe’s Economies Findings from MGA’s detailed impact analysis indicate that in 2018, Teva’s local purchases and payroll supported more than 112,600 jobs, contributed $26.1 billion to gross domestic product (GDP) and generated $3.9 billion in labor income, a measure of aggregate worker wages, across 12 European countries.

Driving Savings and Access with Generic MedicinesTeva is among the top three generic drug companies in more than 20 European markets. At the end of 2018, Teva’s generic pipeline in Europe included 734 approvals and approximately 1,267 marketing authorization applications pending approval.

Teva’s generic medicines provided more than $8.6 billion in savings to healthcare systems across Europe in 2018.

Figure 1. 112,629 Jobs Supported by Teva Across 12 European Countries in 2018

Bulgaria 5,708

France 6,352

Germany 15,990

Italy 7,877

United Kingdom 30,461

Ireland 1,238

Poland 11,875

Spain 6,428

Netherlands 3,235

Hungary8,350

Croatia 6,624

16



Teva in BulgariaWith nearly 1,700 employees in Bulgaria, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic and over-the-counter drug company in Bulgaria, manufacturing more than 330 generic medicines and nearly 60 over-the-counter products. Approximately one of every seven generic prescriptions in Bulgaria is filled with a Teva product.1


лв34M ($21M) in generic

savings attributable to Teva



supported

5,700+jobs

generated

лв104M($64M)

in labor income

contributed

лв598M($370M) to gross domestic product

(GDP)


Positively Impacting Bulgaria’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 5,700 full-time jobs, contributing лв598 million ($370 million) to GDP and generating лв104 million ($64 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines

Teva saved Bulgaria’s healthcare systemлв34M ($21M) in 2018

Table 1. Teva’s Macroeconomic Impact in Bulgaria in 2018



GDP (Millions)

лв $ лв $

Teva’s Direct Economic Activity 1,698 46.4 28.7 178.5 110.6


Total 5,708 104.0 64.4 597.8 370.3

Generic drugs provide significant savings to Bulgaria’s healthcare system. As the leading generic drug company in Bulgaria, Teva’s generics saved the healthcare system an estimated лв34 million ($21 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Bulgaria and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

2. MGA estimate.

18



Teva in CroatiaWith approximately 2,250 employees in Croatia, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is one of the biggest investors in manufacturing and research and development (R&D) in Croatia, with 220 generic medicines, 21 specialty medicines and 49 over-the-counter products. Approximately one of every five generic prescriptions in Croatia is filled with a Teva product.1




generated

kn968M($158M) in labor income

contributed

kn4.1B($676M) to gross


supported

6,600+jobs


Positively Impacting Croatia’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 6,600 full-time jobs, contributing kn4.1 billion ($676 million) to GDP and generating kn968 million ($158 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Croatia and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva is one of the biggest investors in manufacturing and R&D in Croatia, investing kn1.4B+ ($230M) over the last five years in newproduction of sterile medicines, multi-purpose synthesis active pharmaceutical ingredients (APIs) and sterile APIs

Table 1. Teva’s Macroeconomic Impact in Croatia in 2018



GDP (Millions)

kn $ kn $

Teva’s Direct Economic Activity 2,265 353.0 57.6 1,162.0 189.7

Economic Activity Supported by Teva 4,359 614.8 100.4 2,980.2 486.6

Total 6,624 967.8 158.0 4,142.2 676.3



Teva in the Czech Republic With nearly 1,600 employees in the Czech Republic, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in the Czech Republic, and the company’s product portfolio in the country comprises more than 350 medicines. Approximately one of every 10 generic prescriptions in the Czech Republic is filled with a Teva product.1

Kč797M ($37M) in generic savings




supported nearly

8,500jobs

generated

Kč4.9B ($226M) in

labor income

contributed

Kč31.5B ($1.4B) to gross




Positively Impacting the Czech Republic’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 8,500 full-time jobs, contributing Kč31.5 billion ($1.4 billion) to GDP and generating Kč4.9 billion ($226 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to the Czech Republic’s healthcare system. As the leading generic drug company in the Czech Republic, Teva’s generics saved the healthcare system an estimated Kč797 million ($37 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in the Czech Republic and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved the Czech Republic’s healthcare system Kč797M ($37M) in 2018

The Czech Republic is home to one of Teva’s most modern production plants, with an annual capacity of up to11 billion tablets

Teva delivers more than 20 million medicinepackages to the Czech Republic healthcare industry every year

Table 1. Teva’s Macroeconomic Impact in the Czech Republic in 2018



GDP (Millions)

Kč $ Kč $

Teva’s Direct Economic Activity 1,598 1,000.9 46.1 9,870.7 454.5

Economic Activity Supported by Teva 6,893 3,900.3 179.6 21,613.1 995.1

Total 8,491 4,901.2 225.7 31,483.9 1,449.5

2. MGA estimate.

22



Teva in FranceWith more than 325 employees in France, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva offers more than 800 medicines in France and each day, supplies medicines to 22,000 pharmacies and delivers products directly to 1,800 hospitals and clinics. Approximately one of every 15 generic prescriptions in France is filled with a Teva product.1


€196M ($238M) in generic savings




supported nearly

6,400 jobs

generated

€293M($355M) in

labor income

contributed

€1.6B($2.0B) to gross



Positively Impacting France’s EconomyAs an employer and manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to GDP.

Teva’s economic impact in 2018 included supporting nearly 6,400 full-time jobs, contributing €1.6 billion ($2.0 billion) to GDP and generating €293 million ($355 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic MedicinesIn 2018, generic drugs saved France’s healthcare system an estimated €2.9 billion ($3.5 billion).2 Teva is responsible for €196 million ($238 million) of these savings.3

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in France and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva’s 2018 Social Impact highlights in France:

• Donated €13,000 ($15,800) worth of medicines to non-governmental organizations for patients in need

• Donated €10,000 ($12,100) to AIDES, a French non-profit organization that fights HIV/AIDS and hepatitis

• Donated €10,000 ($12,100) to PISTES, a research and physician association that disseminates scientific information

• Donated €10,000 ($12,100) to Société Française d’Etude et de Traitement de la Douleur (SFETD), an association that brings together health professionals to promote care, education and research in pain treatment

Table 1. Teva’s Macroeconomic Impact in France in 2018



GDP (Millions)

€ $ € $


Economic Activity Supported by Teva 6,026 245.2 297.1 910.4 1,103.2

Total 6,352 292.7 354.7 1,616.7 1,959.1

2. Les Entreprises du Médicament en France (LEEM), Bilan Économique – Édition 2018.3. MGA estimate based on Teva’s generic market share in France in 2018.

18%+ of medicines distributed by Teva in France are produced in the country

Teva saved France’s healthcare system €196M ($238M) in 2018

24



Teva in GermanyWith nearly 2,600 employees in Germany, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is one of the leading generic drug companies in Germany and the top supplier of medicines to the healthcare system, manufacturing more than 340 million packs of medicines. Approximately one of every eight generic prescriptions in Germany is filled with a Teva product.1


€1.8B ($2.1B) in generic savings




supported nearly

16,000 jobs

generated

€458M($555M) in

labor income

contributed




Positively Impacting Germany’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 16,000 full-time jobs, contributing more than €4.5 billion ($5.4 billion) to GDP and generating €458 million ($555 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Germany’s healthcare system. As one of the leading generic drug manufacturers in Germany, Teva’s generics saved the healthcare system an estimated €1.8 billion ($2.1 billion) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Germany and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Germany’s healthcare system€1.8B ($2.1B) in 2018

Teva is investing€500M ($606M) in a state-of-the-artbiopharmaceutical plant in Ulm, Germany, one of Europe’s largest modern production sites for biopharmaceuticals

Table 1. Teva’s Macroeconomic Impact in Germany in 2018



GDP (Millions)

€ $ € $

Teva’s Direct Economic Activity 2,553 164.3 199.0 1,912.8 2,318.0

Economic Activity Supported by Teva 13,437 293.7 355.9 2,581.5 3,128.3

Total 15,990 457.9 554.9 4,494.3 5,446.2

2. Based on MGA analysis.



Teva in Hungary With more than 2,100 employees in Hungary, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is a leading generic drug company in Hungary, and nearly 40 million packs of Teva medicines are sold in the country each year. Approximately one of every eight generic prescriptions in Hungary is filled with a Teva product.1

Ft6.9B ($26M) in generic savings




supported nearly

8,400 jobs

generated

Ft57.7B($214M) in

labor income

contributed

Ft198.4B ($734M) to gross




Positively Impacting Hungary’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 8,400 full-time jobs, contributing more than Ft198.4 billion ($734 million) to GDP and generating more than Ft57.7 billion ($214 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Hungary’s healthcare system. As a leading generic drug company in Hungary, Teva’s generics saved the healthcare system an estimated Ft6.9 billion ($26 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Hungary and their patients and caregivers through employee volunteering, programs and partnerships.

Teva saved Hungary’s healthcare system Ft6.9B ($26M) in 2018

Teva has invested more than Ft350B ($1.3B) in capital expenditures and research and development (R&D) in Hungary

Teva’s facility in Debrecen is a cornerstone of Teva R&D and production in Europe

Table 1. Teva’s Macroeconomic Impact in Hungary in 2018



GDP (Millions)

Ft $ Ft $



Total 8,350 57,705.0 213.6 198,429.3 734.3

2. MGA estimate.

28



Teva in IrelandWith more than 700 employees in Ireland, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in Ireland and the largest supplier of prescription medicines to Ireland’s pharmacies. Approximately one of every five generic prescriptions in Ireland is filled with a Teva product.1


€73M ($86M) in estimated generic savings attributable to Teva



supported

1,200+ jobs

generated

€68M($83M) in

labor income

contributed

€351M($425M) to gross



Positively Impacting Ireland’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 1,200 full-time jobs, contributing €351 million ($425 million) to GDP and generating €68 million ($83 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Ireland’s healthcare system. As the leading generic drug company in Ireland, Teva’s generics saved the healthcare system an estimated €73 million ($86 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Ireland and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Ireland’s healthcare system anestimated €73M ($86M) in 2018

Table 1. Teva’s Macroeconomic Impact in Ireland in 2018



GDP (Millions)

€ $ € $


Economic Activity Supported by Teva 531 31.3 37.9 234.5 284.2

Total 1,238 68.2 82.7 350.8 425.2

2. MGA estimate.


Teva in ItalyWith more than 1,300 employees in Italy, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in Italy, offering more than 200 generic medicines, 19 specialty medicines and 30 over-the-counter products. Approximately one of every six generic prescriptions in Italy is filled with a Teva product.1






supported nearly

7,900 jobs

generated

€254M($308M) in

labor income

contributed





Positively Impacting Italy’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 7,900 full-time jobs, contributing €1.7 billion ($2.1 billion) to GDP and generating €254 million ($308 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Italy’s healthcare system. As the leading generic drug company in Italy, Teva’s generics saved Italy’s healthcare system an estimated €776 million ($940 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Italy and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Italy’s healthcare system€776M ($940M)in 2018

Table 1. Teva’s Macroeconomic Impact in Italy in 2018



GDP (Millions)

€ $ € $

Teva’s Direct Economic Activity 1,305 79.4 96.2 696.4 843.8


Total 7,877 254.3 308.1 1,734.3 2,101.6

2. MGA estimate.

32



Teva in the Netherlands With more than 800 employees in the Netherlands, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in the Netherlands, reaching two to three million patients every month. Teva offers the widest range of generic medicines in the Netherlands, and approximately one of every four generic prescriptions is filled with a Teva product.1






supported

3,200+ jobs

generated

€180M ($218M) in

labor income

contributed

€1.4B ($1.7B) to gross



Positively Impacting the Netherlands’ EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 3,200 full-time jobs, contributing €1.4 billion ($1.7 billion) to GDP and generating €180 million ($218 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to the Netherlands’ healthcare system. As the leading generic drug company in the Netherlands, Teva’s generics saved the healthcare system an estimated €722 million ($856 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in the Netherlands and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved the Netherlands’ healthcare system €722M ($856M)in 2018

Table 1. Teva’s Macroeconomic Impact in the Netherlands in 2018



GDP (Millions)

€ $ € $


Economic Activity Supported by Teva 2,402 139.3 168.8 885.6 1,073.1

Total 3,235 180.3 218.5 1,403.1 1,700.3

2. MGA estimate.

34



Teva in Poland With more than 1,100 employees in Poland, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is one of the leading generic drug companies in Poland, delivering almost 600 specialty, generic and over-the-counter medicines across key therapeutic areas to patients. Approximately one of every 12 generic prescriptions in Poland is filled with a Teva product.1


zł317M ($88M) in generic savings




supported nearly

11,900 jobs

generated

zł747M ($215M) in

labor income

contributed

zł6.0B ($1.7B) to gross



Positively Impacting Poland’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 11,900 full-time jobs, contributing zł6.0 billion ($1.7 billion) to GDP and generating zł747 million ($215 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Poland’s healthcare system and patients. As one of the largest generic medicine manufacturers in Poland, Teva’s generic drugs saved the healthcare system an estimated zł317 million ($88 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Poland and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Poland’s healthcare system zł317M ($88M) in 2018

Table 1. Teva’s Macroeconomic Impact in Poland in 2018



GDP (Millions)

zł $ zł $

Teva’s Direct Economic Activity 1,124 162.5 46.7 1,693.5 486.5


Total 11,875 747.3 214.7 5,969.4 1,714.8

2. MGA estimate based on MGA analysis.


Teva in Spain With more than 800 employees in Spain, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is one of the leading generic drug companies in Spain, providing more than 1,400 generic medicines and 110 specialty medicines. Approximately one of every 12 generic prescriptions in Spain is filled with a Teva product.1






supported

6,400+ jobs

generated

€178M ($216M) in

labor income

contributed

€1.0B ($1.3B) to gross




Positively Impacting Spain’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 6,400 full-time jobs, contributing €1.0 billion ($1.3 billion) to GDP and generating €178 million ($216 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines In 2018, generic drugs saved Spain’s healthcare system and patients an estimated €1 billion ($1.2 billion).2 As one of the leading generic drug companies in Spain, Teva was responsible for €86 million ($104 million) of these savings.3

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Spain and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Spain’s healthcare system €86M($104M) in 2018

Teva provides 110+ innovative specialtymedicines in Spain

Table 1. Teva’s Macroeconomic Impact in Spain in 2018



GDP (Millions)

€ $ € $



Total 6,428 178.0 215.7 1,035.2 1,254.5

2. Spanish Generic Medicines Association (AESEG).3. MGA estimate based on Teva’s generic market share in Spain in 2018.

38



Teva in the United Kingdom With nearly 1,300 employees in the United Kingdom (UK), Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in the UK, with a strong presence in over-the-counter products. Approximately one of every five generic prescriptions in the UK is filled with a Teva product.1


£3.0B ($4.1B) in estimated generic savings attributable to Teva



supported nearly

30,500 jobs

generated

£927M ($1.3B) in

labor income

contributed

£6.0B($8.2B) to gross


39

Positively Impacting the UK EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 30,500 full-time jobs, contributing £6.0 billion ($8.2 billion) to GDP and generating £927 million ($1.3 billion) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines In 2018, generic drugs saved the UK healthcare system an estimated £13.5 billion ($18.6 billion).2 As the leading generic drug company in the UK, Teva was responsible for an estimated £3.0 billion ($4.1 billion) of these savings.3

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in the UK and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved the UK healthcare system an estimated £3.0B ($4.1B) in 2018

Table 1. Teva’s Macroeconomic Impact in the UK in 2018



GDP (Millions)

£ $ £ $

Teva’s Direct Economic Activity 1,289 51.5 71.0 2,871.3 3,958.7

Economic Activity Supported by Teva 29,172 875.8 1,207.5 3,106.5 4,283.0

Total 30,461 927.3 1,278.5 5,977.8 8,241.7

2. British Generic Manufacturers Association.3. MGA estimate based on Teva’s generic market share in the UK in 2018.




Teva in Chile With more than 800 employees in Chile, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is a leading generic drug company in Chile and the country leader in bioequivalents. Approximately one of every six generic prescriptions in Chile is filled with a Teva product.1

CLP$84.8B ($132M) in generic savings




supported

4,500+ jobs

generated

CLP$83.4B ($130M) in

labor income

contributed

CLP$267.1B ($416M) to gross




Positively Impacting Chile’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 4,500 full-time jobs, contributing CLP$267.1 billion (US$416 million) to GDP and generating CLP$83.4 billion (US$130 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Chile’s healthcare system. As a leading generic drug company in Chile, Teva’s generics saved the healthcare system an estimated CLP$84.8 billion (US$132 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Chile and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva’s 2018 Social Impact highlights in Chile:

• Over a 15-year partnership, employees and Teva have donated approximately CLP$642 million (US$1 million) to Fundación Nuestros Hijos

• Became the first pharmaceutical company to obtain “Huella Chile” certification, demonstrating compliance with environmental regulations and measures and actions to reduce greenhouse gas emissions

Teva saved saved Chile’s healthcare system CLP$84.8B (US$132M) in 2018

In Chile, Teva has two state-of-the-art manufacturing facilities in Maipú, as well as high-volume, technologically advanced distribution facilities

Teva has 500+ registered generic, bioequivalent andspecialty medicines in Chile

Table 1. Teva’s Macroeconomic Impact in Chile in 2018



GDP (Millions)

CLP$ US$ CLP$ US$

Teva’s Direct Economic Activity 811 22,852.6 35.6 65,985.7 102.8


Total 4,534 83,350.6 129.8 267,141.3 416.0

2. MGA estimate.


Teva in IsraelWith more than 4,800 employees in Israel, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Headquartered in Israel, Teva is the leading provider of medicines in the country. Israel houses Teva commercial and distribution operations, two research and development (R&D) centers and two manufacturing sites, including one for finished products and one for active pharmaceutical ingredients (APIs). Teva is also a partner in Sanara Ventures, an Israel-based healthcare-focused accelerator and incubator, along with Philips Healthcare and Israel Innovation Authority, and has many biopharmaceutical R&D collaborations with universities across the country. Approximately one of every three generic prescriptions is filled with a Teva product.1 Rotem Strategy conducted an independent analysis of Teva’s economic impact in Israel.

₪1.4B ($400M) in generic savings




supported nearly

19,100 jobs

contributed approximately

₪2.8B ($787M) to government

and public sector revenues

contributed

₪10.4B ($3.0B) to gross



1. Rotem Strategy, 2018. Teva’s Economic Contribution to the State of Israel.


Positively Impacting Israel’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 19,100 full-time jobs and contributing ₪10.4 billion ($3.0 billion) to GDP and approximately ₪2.8 billion ($787 million) in direct national revenues (equivalent to approximately 0.9% of Israel’s total government revenue).2 See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic MedicinesGeneric drugs saved Israel’s healthcare system an estimated ₪4.1 billion ($1.2 billion) in 2017, equivalent to 4% of the national healthcare expenditure and 12% of Israel’s 2017 healthcare budget.2 With 30% share of Israel’s generic drug market, Teva is responsible for ₪1.4 billion ($400 million) of these savings.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Israel and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Israel’s healthcare system ₪1.4B ($400M) in 2018

Teva contributed €70M ($20M) in royalties to academic research institutions in Israel (equivalent to 7% of national government budget for higher education)

Table 1. Teva’s Macroeconomic Impact in Israel in 2018


* Includes jobs provided by suppliers and academic institutions, jobs attributable to employee private spending, public sector jobs and pharmaceutical industry jobs.

JobsGovernment and Public

Sector Revenues (Millions)

GDP (Millions)

₪ $ ₪ $

Teva’s Direct Economic Activity 4,812 1,192 339 6,243 1,776

Economic Activity Supported by Teva* 14,267 1,573 448 4,175 1,188

Total 19,079 2,765 787 10,418 2,964

2. Rotem Strategy, 2018. Teva’s Economic Contribution to the State of Israel.

₪1.5B ($427M)invested in R&D and technology in Israel annually


Teva in Japan With more than 1,600 employees in Japan, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is a leading generic drug company in Japan. Approximately one of every 30 generic prescriptions in Japan is filled with a Teva product.1


¥39.1B ($355M) in generic savings



generated

¥65.7B ($595M) in

labor income

contributed

¥304.7B($2.8B) to gross


supported

9,400+ jobs


Positively Impacting Japan’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 9,400 full-time jobs, contributing ¥304.7 billion ($2.8 billion) to GDP and generating ¥65.7 billion ($595 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Japan’s healthcare system. As a leading generic drug company in Japan, Teva’s generics saved the healthcare system an estimated ¥39.1 billion ($355 million) in 2018.2

Teva saved Japan’s healthcare system ¥39.1B ($355M) in 2018

Teva has 3 manufacturing sites in Japan—in Takayama, Koka and Minakuchi

Table 1. Teva’s Macroeconomic Impact in Japan in 2018



GDP (Millions)

¥ $ ¥ $


Economic Activity Supported by Teva 7,845 54,343.1 492.5 229,859.2 2,083.2

Total 9,446 65,659.0 595.1 304,655.6 2,761.1

2. MGA estimate based on Teva’s generic market share in Japan in 2018 and Japanese Ministry of Health, Labour and Welfare fiscal year 2017 generic drug savings estimate.

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Japan and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva’s 2018 Social Impact highlights in Japan:

• Hosted annual open houses at Takayama and Koka facilities with interactive learning sessions for the local community

• Supported learning initiatives at a local children’s home with regular visits from Takayama facility employees


Teva in Russia With more than 900 employees in Russia, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the leading generic drug company in Russia. Approximately one of every 22 generic prescriptions in Russia is filled with a Teva product.1



Ꝑ10.8B ($173M) in generic savings


contributed

Ꝑ123.2B ($2.0B) to gross


generated

Ꝑ16.8B ($267M) in

labor income

supported

18,700+ jobs


Positively Impacting Russia’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting more than 18,700 full-time jobs, contributing ₽123.2 billion ($2.0 billion) to GDP and generating ₽16.8 billion ($267 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Russia’s healthcare system. As the leading generic drug company in Russia, Teva’s generics saved the healthcare system an estimated ₽10.8 billion ($173 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Russia and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Russia’s healthcare system ₽10.8B ($173M) in 2018

Teva’s 13,000 m² manufacturing facility in Yaroslavl has the capacity toproduce 2 billion tablets per year

Table 1. Teva’s Macroeconomic Impact in Russia in 2018



GDP (Millions)

₽ $ ₽ $

Teva’s Direct Economic Activity 933 2,234.3 35.6 35,973.7 572.4

Economic Activity Supported by Teva 17,813 14,525.8 231.1 87,190.8 1,387.5

Total 18,746 16,760.1 266.7 123,164.5 1,959.9

2. MGA estimate.


Teva in UkraineWith more than 300 employees in Ukraine, Teva Pharmaceutical Industries Ltd. (hereinafter “Teva”), including all its subsidiaries, has extensive operations that span all aspects of bringing medicines to market. Teva is the largest international pharmaceutical company and a leading generic drug company in Ukraine. Approximately one of every 22 generic prescriptions in Ukraine is filled with a Teva product.1


₴492M ($18M) in generic savings



contributed

₴12.2B ($450M) to gross


generated

₴1.6B ($58M) in

labor income

supported nearly

2,100 jobs


Positively Impacting Ukraine’s EconomyAs an employer and a manufacturer, Teva creates jobs and contributes to economic output. Beyond direct expenditures, Teva’s spending initiates a series of income creation, spending and re-spending that support other jobs and contribute to additional GDP.

Teva’s economic impact in 2018 included supporting nearly 2,100 full-time jobs, contributing ₴12.2 billion ($450 million) to GDP and generating ₴1.6 billion ($58 million) in labor income, a measure of aggregate worker wages. See Table 1 for a breakdown of this impact.

Driving Savings and Access with Generic Medicines Generic drugs provide significant savings to Ukraine’s healthcare system. As a leading generic drug company in Ukraine, Teva’s generics saved the healthcare system an estimated ₴492 million ($18 million) in 2018.2

Making a Positive Social ImpactTeva promotes health and increases access to treatment for patients, while cultivating a culture of compliance, ethics and transparency. Teva supports communities in Ukraine and their patients and caregivers through monetary and product donations, employee volunteering, programs and partnerships.

Teva saved Ukraine’s healthcare system ₴492M ($18M) in 2018

Teva has the largest portfolio of international pharmaceutical companies in Ukraine, with more than 15 specialty medicines and 600 generic medicines

Table 1. Teva’s Macroeconomic Impact in Ukraine in 2018



GDP (Millions)

₴ $ ₴ $

Teva’s Direct Economic Activity 331 185.1 6.8 3,141.7 115.6


Total 2,089 1,580.5 58.1 12,228.4 449.8

2. MGA estimate.

This report includes certain information that MGA and/or Teva deemed fit to present, and it is not intended to supersede or otherwise derogate from any information provided by Teva in its public disclosures with the U.S. Securities and Exchange Commission and/or that is otherwise available on the website www.Tevapharm.com. This report includes a summary of the issues addressed herein, in specific context, and not the full information that Teva has on such matters, and it is not intended to supersede or replace the need to review public reports and statements published by Teva in accordance with applicable laws or otherwise. In any event of discrepancy between the figures and/or data contained in this report and the figures and/or data contained in Teva’s public reports, figures and/or data contained in public reports shall be deemed the correct ones.

http://www.Tevapharm.com

Teva Global Economic Impact Report · Teva Economic Impact Report 5 In 2018, Teva’s economic...

Documents

Transcript of Teva Global Economic Impact Report · Teva Economic Impact Report 5 In 2018, Teva’s economic...